serotonin reuptake inhibitor (SSRI)

PreclinicalSmall molecule

serotonin reuptake inhibitor (SSRI) is one of 9 small molecule programs targeting Premature Ejaculation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature EjaculationActive, not recruiting

Premature EjaculationPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Premature Ejaculation

#DrugCompanyPhaseTrials

Viagra

VViatris Specialty LLC

Approved

1 2

Xylocaine

MMEDRx USA, Inc.

Approved

1 3

Botox

AbbVie

Phase 3

1 4

Standard Treatment

Boehringer Ingelheim

Phase 3

1 5

BP1.4979

BBioprojet

Phase 2

1 6

Botox

RRevance Therapeutics, Inc.

Preclinical

1 7

Dapoxetine Hydrochloride

Johnson & Johnson

Preclinical

2 8

Bont-a

SSir Run Run Shaw Hospital

Preclinical

1 9

serotonin reuptake inhibitor (SSRI)

MMedipol University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Premature Ejaculation

NCT07067970

Clinical

Trials by Indication[1]

Premature Ejaculation1 trial

Comparison of the Efficacy and Safety of Dapoxetine, Kegel Exercises, and Acupuncture in the Treatment of Premature Ejaculation: A Randomized, Double-Blind, Placebo-Controlled Trial

Not yet recruiting·MMedipol University·N/A·NCT07067970·250 enrolled

Pain Management1 trial

Effectiveness of Dry Needling Adjuvant to Selective Serotonin Reputake Inhibitors vs TP Injection for Pain Management

Active, not recruiting·SSuperior University·N/A·NCT06457581·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for serotonin reuptake inhibitor (SSRI). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — serotonin reuptake inhibitor (SSRI) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for serotonin reuptake inhibitor (SSRI). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medipol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedipol University

serotonin reuptake inhibitor (SSRI)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Premature Ejaculation1 trial

Pain Management1 trial

References

Drug Info

Quick Facts

Related News